Nausea profile of amylin analogues compared with GLP-1 agonists

Nausea profile of amylin analogues compared with GLP-1 agonists Writing it up because I had to work it out twice and would rather nobody else did.

I have spent a fortnight trying to pin nausea profile of amylin analogues down and I want to set out where I have got to, because I suspect the honest answer is duller than the thread this will produce.

What I have: a consistent observation across a small number of cases, collected the same way each time. What I do not have: any controlled comparison, or any reason to think my cases are representative.

The specific question is whether the pattern survives once the obvious confounder is removed. I cannot remove it with what I have.

The opening post describes the usual case. This is about the unusual one.

Nausea appears in the amylin-analogue literature as it does in the incretin literature, and the two are not additive in a simple way when the drugs are combined. The combination trials report tolerability separately for that reason.

Fair, and the limits you put on it are the part I will remember.

Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and analytically straightforward to confirm by LC-MS.

Sensible. I would want the same detail before I acted on it either.

That is a cleaner way of putting what I was circling around.

Answering the question post #52 raises rather than the one it answers.

Nausea profile of amylin analogues: the historical agent pramlintide required multiple daily doses and had a difficult tolerability profile. A weekly formulation is a substantially different proposition and data from that is more relevant than data from pramlintide.

The disagreement above is smaller than it looks once the terms are fixed.

Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably together and both are true.

Nausea profile of amylin analogues is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until someone says which one is being asked for.